Cargando…

Effectiveness of Shuxuening injection in coronary heart disease: a systematic review and meta-analysis

Background: Coronary heart disease (CHD) poses a serious threat to public health, and the current medical management still faces significant challenges. Reliable evidence on the efficacy of Shuxuening injection (SXNI) in CHD is still lacking, even though it is widely used in China. Purpose: To evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Menglong, Sun, Tianye, Ji, Zhaochen, Ma, Yucong, Zhao, Min, Yang, Fengwen, Zhang, Junhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544985/
https://www.ncbi.nlm.nih.gov/pubmed/37790809
http://dx.doi.org/10.3389/fphar.2023.1265603
_version_ 1785114586111803392
author Shi, Menglong
Sun, Tianye
Ji, Zhaochen
Ma, Yucong
Zhao, Min
Yang, Fengwen
Zhang, Junhua
author_facet Shi, Menglong
Sun, Tianye
Ji, Zhaochen
Ma, Yucong
Zhao, Min
Yang, Fengwen
Zhang, Junhua
author_sort Shi, Menglong
collection PubMed
description Background: Coronary heart disease (CHD) poses a serious threat to public health, and the current medical management still faces significant challenges. Reliable evidence on the efficacy of Shuxuening injection (SXNI) in CHD is still lacking, even though it is widely used in China. Purpose: To evaluate the efficacy of SXNI combination therapy in treating CHD. Methods: A systematic search of eight databases was conducted to identify relevant randomized controlled trials (RCTs) from the inception of each database until June 2023. ROB 2.0, RevMan 5.4, and Stata 15.1 were used for quality evaluation and data analysis. The Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) approach was used to evaluate the quality of evidence. Results: A total of 3,779 participants from 39 studies were included. The results showed SXNI combination therapy increased the clinical efficacy and decreased the frequency and duration of angina. Furthermore, SXNI combination therapy improved cardiac function of patients by decreasing LVEDD, and increased CI, CO, and LVEF. It also improved blood lipid profiles by increasing HDL, decreasing TC, TG, and LDL. The thrombosis factors of patients were also improved by decreasing FIB, PV, HCT, and HS. Moreover, SXNI combination therapy was superior to the conventional treatment in improving CRP levels, increasing ECG efficacy and BNP. However, due to the limited safety information, reliable safety conclusions could not be drawn. Furthermore, the levels of evidence ranged from very low to moderate due to publication bias and heterogeneity. Conclusion: SXNI can effectively improve angina symptoms, clinical efficacy, cardiac function, blood lipid indicators, and thrombosis factors of patients with CHD. However, more multi-center and large-sample studies are needed to confirm the conclusions due to the limitations of this study. Registration https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=399606; Identifier: CRD42023433292.
format Online
Article
Text
id pubmed-10544985
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105449852023-10-03 Effectiveness of Shuxuening injection in coronary heart disease: a systematic review and meta-analysis Shi, Menglong Sun, Tianye Ji, Zhaochen Ma, Yucong Zhao, Min Yang, Fengwen Zhang, Junhua Front Pharmacol Pharmacology Background: Coronary heart disease (CHD) poses a serious threat to public health, and the current medical management still faces significant challenges. Reliable evidence on the efficacy of Shuxuening injection (SXNI) in CHD is still lacking, even though it is widely used in China. Purpose: To evaluate the efficacy of SXNI combination therapy in treating CHD. Methods: A systematic search of eight databases was conducted to identify relevant randomized controlled trials (RCTs) from the inception of each database until June 2023. ROB 2.0, RevMan 5.4, and Stata 15.1 were used for quality evaluation and data analysis. The Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) approach was used to evaluate the quality of evidence. Results: A total of 3,779 participants from 39 studies were included. The results showed SXNI combination therapy increased the clinical efficacy and decreased the frequency and duration of angina. Furthermore, SXNI combination therapy improved cardiac function of patients by decreasing LVEDD, and increased CI, CO, and LVEF. It also improved blood lipid profiles by increasing HDL, decreasing TC, TG, and LDL. The thrombosis factors of patients were also improved by decreasing FIB, PV, HCT, and HS. Moreover, SXNI combination therapy was superior to the conventional treatment in improving CRP levels, increasing ECG efficacy and BNP. However, due to the limited safety information, reliable safety conclusions could not be drawn. Furthermore, the levels of evidence ranged from very low to moderate due to publication bias and heterogeneity. Conclusion: SXNI can effectively improve angina symptoms, clinical efficacy, cardiac function, blood lipid indicators, and thrombosis factors of patients with CHD. However, more multi-center and large-sample studies are needed to confirm the conclusions due to the limitations of this study. Registration https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=399606; Identifier: CRD42023433292. Frontiers Media S.A. 2023-09-18 /pmc/articles/PMC10544985/ /pubmed/37790809 http://dx.doi.org/10.3389/fphar.2023.1265603 Text en Copyright © 2023 Shi, Sun, Ji, Ma, Zhao, Yang and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Shi, Menglong
Sun, Tianye
Ji, Zhaochen
Ma, Yucong
Zhao, Min
Yang, Fengwen
Zhang, Junhua
Effectiveness of Shuxuening injection in coronary heart disease: a systematic review and meta-analysis
title Effectiveness of Shuxuening injection in coronary heart disease: a systematic review and meta-analysis
title_full Effectiveness of Shuxuening injection in coronary heart disease: a systematic review and meta-analysis
title_fullStr Effectiveness of Shuxuening injection in coronary heart disease: a systematic review and meta-analysis
title_full_unstemmed Effectiveness of Shuxuening injection in coronary heart disease: a systematic review and meta-analysis
title_short Effectiveness of Shuxuening injection in coronary heart disease: a systematic review and meta-analysis
title_sort effectiveness of shuxuening injection in coronary heart disease: a systematic review and meta-analysis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544985/
https://www.ncbi.nlm.nih.gov/pubmed/37790809
http://dx.doi.org/10.3389/fphar.2023.1265603
work_keys_str_mv AT shimenglong effectivenessofshuxueninginjectionincoronaryheartdiseaseasystematicreviewandmetaanalysis
AT suntianye effectivenessofshuxueninginjectionincoronaryheartdiseaseasystematicreviewandmetaanalysis
AT jizhaochen effectivenessofshuxueninginjectionincoronaryheartdiseaseasystematicreviewandmetaanalysis
AT mayucong effectivenessofshuxueninginjectionincoronaryheartdiseaseasystematicreviewandmetaanalysis
AT zhaomin effectivenessofshuxueninginjectionincoronaryheartdiseaseasystematicreviewandmetaanalysis
AT yangfengwen effectivenessofshuxueninginjectionincoronaryheartdiseaseasystematicreviewandmetaanalysis
AT zhangjunhua effectivenessofshuxueninginjectionincoronaryheartdiseaseasystematicreviewandmetaanalysis